To test this hypothesis, we established a mouse model containing both the primary tumor and the distal lesion and designed a combination therapy regimen of Nano-IFNγ/Zole and iRFA according to the flowchart of Figure 7A. As shown in Figure 7B-E and Figure S56, administration of Nano-IFNγ/Zole after iRFA not only inhibited tumor recurrence in situ, but also limited the growth of distal tumors. The gene discussed is IFNG; the disease is neoplasm.